AXOLTIS PHARMA
Axoltis pharma is a biotech company that develops drugs for degenerative and traumatic neurological disorders.
AXOLTIS PHARMA
Social Links:
Industry:
Biotechnology Health Care Pharmaceutical
Founded:
2003-01-01
Address:
Lyon, Rhone-Alpes, France
Country:
France
Website Url:
http://www.axoltis.com
Total Employee:
1+
Status:
Active
Contact:
+33 (0)472 621 736
Email Addresses:
[email protected]
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Tag Manager Euro Google Font API Google Analytics Google Maps WordPress
Similar Organizations
ARCEDI Biotech
ARCEDI Biotech is a biotech company, develops technologies and methods for detecting and diagnosing rare cancer cells.
NephroDI Therapeutics
NephroDI Therapeutics is a biopharmaceutical company that focuses on the concentration disorders of the kidney.
PCI Pharma Services
PCI Pharma Services is a provider of outsourced services to the global pharmaceutical market.
Prolocor
Prolocor is a biotechnology company that develops diagnostic tests for cardiovascular diseases.
Synaxys
Synaxys is a research company for drug discovery for neurological diseases.
Trevarx Biomedical
Trevarx Biomedical is a biomedical startup that develops new radiopharmaceuticals.
Current Employees Featured
Founder
Official Site Inspections
http://www.axoltis.com Semrush global rank: 9.99 M Semrush visits lastest month: 286
- Host name: cluster020.hosting.ovh.net
- IP address: 46.105.57.169
- Location: Saint-Ouen France
- Latitude: 48.9067
- Longitude: 2.3339
- Timezone: Europe/Paris
- Postal: 93400
More informations about "Axoltis pharma"
www.axoltis.com
We would like to show you a description here but the site won’t allow us.See details»
Axoltis pharma - Crunchbase Company Profile & Funding
Axoltis pharma is a biotech company that develops drugs for degenerative and traumatic neurological disorders. New. ... Experience the new Crunchbase, …See details»
Axoltis Pharma - LinkedIn
Axoltis pharma is a biopharmaceutical company dedicated to develop a first-in-class disease-modifying drug to treat patients with neurodegenerative or traumatic neurological disorders …See details»
Axoltis Pharma 2025 Company Profile: Valuation, Funding
Axoltis Pharma General Information Description. Operator of a biotechnology company intended to treat patients suffering from severe neurological disorders. The company's drugs assist …See details»
Axoltis: Revenue, Worth, Valuation & Competitors 2025
About Axoltis. Axoltis is a Biotech related company based in Lyon with 15 employees an estimated revenue of $2.3M, and. It has 10 competitors including Dermavant Sciences, …See details»
Axoltis Pharma - The Org
Axoltis pharma is a biopharmaceutical company dedicated to develop a first-in-class disease-modifying drug to treat patients with neurodegenerative or traumatic neurological disorders …See details»
Axoltis Pharma - VentureRadar
Similar Companies: Nosopharm France n/a Nosopharm is an innovative biotechnology company headquartered in Lyon (France) and specialized in the research and development of new …See details»
Axoltis Pharma - Company Profile and News - Bloomberg Markets
Company profile page for Axoltis Pharma including stock price, company news, executives, board members, and contact informationSee details»
Axoltis Pharma - Craft
Axoltis Pharma has 5 employees across 2 locations. See insights on Axoltis Pharma including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft.See details»
AXOLTIS Pharma - Lyonbiopôle
Strategic application domain: Human Medicine Application market: Neurology & Mental Health Disorders Type of activity: Therapeutics, Pharma or Biotech Technologies: Regenerative …See details»
Axoltis Pharma - Products, Competitors, Financials, Employees ...
Axoltis Pharma welcomes Jean-Guillaume Lafay as member of Supervisory Board Serial entrepreneur in biotech, Mr. Lafay’s decades of experience, his vision and network will bolster …See details»
Axoltis pharma Overview | SignalHire Company Profile
Axoltis pharma is a private company. The company currently specializes in the Biotechnology area. The Axoltis pharma annual revenue is estimated at < 1M ... Organization Website: …See details»
Axoltis pharma - Overview, News & Similar companies - ZoomInfo
Jul 27, 2023 Axoltis Pharma is a biopharmaceutical company dedicated to develop first-in-class disease-modifying drugs to treat patients with degenerative or traumatic neurological disorders …See details»
Axoltis Pharma SA - Drug pipelines, Patents, Clinical trials - Synapse
Axoltis Pharma is a French biopharmaceutical company dedicated to developing a first-in-class disease-modifying drug to treat patients with neurodegenerative or traumatic neurological …See details»
Axoltis pharma - Tech Stack, Apps, Patents & Trademarks
Axoltis pharma uses 12 technology products and services including HTML5, Apache Server, and Microsoft Outlook, according to G2 Stack. Axoltis pharma is actively using 28 technologies for …See details»
Axoltis Pharma presents promising results from phase 1b clinical …
Dec 12, 2023 Axoltis recently presented these phase 1b results, combined with encouraging findings from the company’s preclinical studies, at Neuroscience 2023, the annual meeting of …See details»
InSilicoTrials, Axoltis to develop drugs for neurological disorders
Jul 28, 2023 Axoltis CEO Yann Godfrin stated: “Integrating their industry-leading AI and computational modelling solutions in the development plan of our promising disease-modifying …See details»
Axoltis Pharma receives authorization to launch SEALS - phase II ...
Www.axoltis.com Corporate contact Axoltis Pharma (headquarters) Axoltis Pharma (offices) 15-17 rue Pré de la Reine 60 avenue Rockefeller 63100 CLERMONT FERRAND 69008 LYON …See details»
Axoltis Pharma receives authorization to launch SEALS – phase II ...
Apr 10, 2024 Axoltis Pharma, a French biopharma company, develops innovative drugs for neurodegenerative and neurotraumatic diseases with a high unmet medical need. …See details»
InSilicoTrials and Axoltis Pharma Collaborate to Advance …
Jul 27, 2023 Given that Axoltis drug candidate NX210c targets these features, the collaboration with InSilicoTrials holds great promise for supporting CNS functions in a wide range of …See details»